Carbonated soft drinks alter hepatic cytochrome P450 isoform expression in Wistar rats

Alkhedaide,Adel; Soliman,Mohamed  Mohamed; Ibrahim,Zein  Shaban

doi:10.3892/br.2016.762

Carbonated soft drinks alter hepatic cytochrome P450 isoform expression in Wistar rats

Authors:
- Adel Alkhedaide
- Mohamed Mohamed Soliman
- Zein Shaban Ibrahim
View Affiliations

Affiliations: Medical Laboratory Department, Faculty of Applied Medical Sciences, Ta'if University, Turabah, Mecca 21411, Saudi Arabia, Department of Physiology, College of Medicine, Ta'if University, Ta'if, Mecca 21944, Saudi Arabia
Published online on: September 26, 2016 https://doi.org/10.3892/br.2016.762
Pages: 607-612

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the current study was to examine the effects of chronic consumption of soft drinks (SDs) on hepatic oxidative stress and cytochrome P450 enzymes (CYPs) expression in the livers of Wistar rats. For 3 consecutive months, the rats had free access to three different soft drinks, Coca‑Cola, Pepsi‑Cola and 7‑UP. The rats were subsequently compared with control group rats that had consumed water. Blood and hepatic tissue samples were assayed for the changes in antioxidants, liver function biomarkers and hepatic gene expression for different isoforms of hepatic CYP. The results indicated that SD consumption (SDC) decreased serum antioxidant levels and increased malondialdehyde secretion, and increased liver biomarkers (glutamate pyruvate transaminase and glutamate oxaloacetate). SD induced alterations in mRNA expression of hepatic antioxidants and cytochrome isoforms. The expression of peroxidase, catalase, CYP1A2, CYP3A2 and CYP2C11 in the liver were upregulated following SDC. By contrast, CYP2B1 was downregulated after 3 months of SDC in liver tissue samples. Thus, the present findings indicate that SDs induced oxidative stress in the liver of Wistar rats and for the first time, to the best of our knowledge, indicate that SDC disrupts hepatic CYP enzymes that may affect drug metabolism. Therefore, drug‑dosing programs should be carefully designed to take these novel findings into consideration for the treatment of diseases.

View Figures

View References

1	Nielsen SJ and Popkin BM: Changes in beverage intake between 1977 and 2001. Am J Prev Med. 27:205–210. 2004. View Article : Google Scholar : PubMed/NCBI
2	Adjene JO, Ezeoke JC and Nwose EU: Histological effects of chronic consumption of soda pop drinks on kidney of adult Wister rats. N Am J Med Sci. 2:215–217. 2010.PubMed/NCBI
3	Amato D, Maravilla A, García-Contreras F and Paniagua R: Soft-drinks and health. Rev Invest Clin. 49:387–395. 1997.(In Spanish). PubMed/NCBI
4	Amato D, Maravilla A, Montoya C, Gaja O, Revilla C, Guerra R and Paniagua R: Acute effects of soft drink intake on calcium and phosphate metabolism in immature and adult rats. Rev Invest Clin. 50:185–189. 1998.PubMed/NCBI
5	Rapuri PB, Gallagher JC, Kinyamu HK and Ryschon KL: Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr. 74:694–700. 2001.PubMed/NCBI
6	Swinburn BA, Caterson I, Seidell JC and James WP: Diet, nutrition and the prevention of excess weight gain and obesity. Public Health Nutr 7 (1A). 123–146. 2004.
7	Palmer JR, Boggs DA, Krishnan S, Hu FB, Singer M and Rosenberg L: Sugar-sweetened beverages and incidence of type 2 diabetes mellitus in African American women. Arch Intern Med. 168:1487–1492. 2008. View Article : Google Scholar : PubMed/NCBI
8	Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC and Hu FB: Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr. 89:1037–1042. 2009. View Article : Google Scholar : PubMed/NCBI
9	Santucci R, Levêque D and Herbrecht R: Cola beverage and delayed elimination of methotrexate. Br J Clin Pharmacol. 70:762–764. 2010. View Article : Google Scholar : PubMed/NCBI
10	Guengerich FP: Cytochrome p450 and chemical toxicology. Chem Res Toxicol. 21:70–83. 2008. View Article : Google Scholar : PubMed/NCBI
11	Fowler S and Zhang H: In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: Current status on methodologies and their utility for predicting drug-drug interactions. AAPS J. 10:410–424. 2008. View Article : Google Scholar : PubMed/NCBI
12	Lazarou J, Pomeranz BH and Corey PN: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA. 279:1200–1205. 1998. View Article : Google Scholar : PubMed/NCBI
13	Lee JH, Suh OK and Lee MG: Pharmacokinetic changes in drugs during protein-calorie malnutrition: Correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes. Arch Pharm Res. 27:693–712. 2004. View Article : Google Scholar : PubMed/NCBI
14	Platt DE, Ghassibe-Sabbagh M, Salameh P, Salloum AK, Haber M, Mouzaya F, Gauguier D, Al-Sarraj Y, El-Shanti H, Zalloua PA, et al: Caffeine Impact on Metabolic Syndrome Components Is Modulated by a CYP1A2 Variant. Ann Nutr Metab. 68:1–11. 2016. View Article : Google Scholar : PubMed/NCBI
15	El-Terras A, Soliman MM, Alkhedaide A, Attia HF, Alharthy A and Banaja AE: Carbonated soft drinks induce oxidative stress and alter the expression of certain genes in the brains of Wistar rats. Mol Med Rep. 13:3147–3154. 2016.PubMed/NCBI
16	Soliman MM, Baiomy AA and Yassin MH: Molecular and histopathological study on the ameliorative effects of curcumin against lead acetate-induced hepatotoxicity and nephrototoxicity in Wistar rats. Biol Trace Elem Res. 167:91–102. 2015. View Article : Google Scholar : PubMed/NCBI
17	Hensley K, Robinson KA, Gabbita SP, Salsman S and Floyd RA: Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med. 28:1456–1462. 2000. View Article : Google Scholar : PubMed/NCBI
18	Alkhedaide A, Soliman MM, Salah-Eldin AE, Ismail TA, Alshehiri ZS and Attia HF: Chronic effects of soft drink consumption on the health state of Wistar rats: A biochemical, genetic and histopathological study. Mol Med Rep. 13:5109–51017. 2016.PubMed/NCBI
19	Niki E: Lipid peroxidation: Physiological levels and dual biological effects. Free Radic Biol Med. 47:469–484. 2009. View Article : Google Scholar : PubMed/NCBI
20	Horton AA and Fairhurst S: Lipid peroxidation and mechanisms of toxicity. Crit Rev Toxicol. 18:27–79. 1987. View Article : Google Scholar : PubMed/NCBI
21	Blair IA: DNA adducts with lipid peroxidation products. J Biol Chem. 283:15545–15549. 2008. View Article : Google Scholar : PubMed/NCBI
22	Łuczaj W and Skrzydlewska E: DNA damage caused by lipid peroxidation products. Cell Mol Biol Lett. 8:391–413. 2003.PubMed/NCBI
23	Oberley TD and Oberley LW: Antioxidant enzyme levels in cancer. Histol Histopathol. 12:525–535. 1997.PubMed/NCBI
24	Saydam N, Kirb A, Demir O, Hazan E, Oto O, Saydam O and Güner G: Determination of glutathione, glutathione reductase, glutathione peroxidase and glutathione S-transferase levels in human lung cancer tissues. Cancer Lett. 119:13–19. 1997. View Article : Google Scholar : PubMed/NCBI
25	Zaher H, Buters JT, Ward JM, Bruno MK, Lucas AM, Stern ST, Cohen SD and Gonzalez FJ: Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol Appl Pharmacol. 152:193–199. 1998. View Article : Google Scholar : PubMed/NCBI
26	Faber MS, Jetter A and Fuhr U: Assessment of CYP1A2 activity in clinical practice: Why, how, and when? Basic Clin Pharmacol Toxicol. 97:125–134. 2005. View Article : Google Scholar : PubMed/NCBI
27	Gonzalez FJ: Molecular genetics of the P-450 superfamily. Pharmacol Ther. 45:1–38. 1990. View Article : Google Scholar : PubMed/NCBI
28	Gibson GG, Plant NJ, Swales KE, Ayrton A and El-Sankary W: Receptor-dependent transcriptional activation of cytochrome P4503A genes: Induction mechanisms, species differences and interindividual variation in man. Xenobiotica. 32:165–206. 2002. View Article : Google Scholar : PubMed/NCBI
29	Sumida A, Kinoshita K, Fukuda T, Matsuda H, Yamamoto I, Inaba T and Azuma J: Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem Biophys Res Commun. 262:499–503. 1999. View Article : Google Scholar : PubMed/NCBI
30	Nedelcheva V and Gut I: P450 in the rat and man: Methods of investigation, substrate specificities and relevance to cancer. Xenobiotica. 24:1151–1175. 1994. View Article : Google Scholar : PubMed/NCBI
31	Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J and Schuetz EG: Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 12:121–132. 2002. View Article : Google Scholar : PubMed/NCBI
32	Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al: P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1–42. 1996. View Article : Google Scholar : PubMed/NCBI
33	Shayeganpour A, El-Kadi AO and Brocks DR: Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: The contribution of cytochrome P450 3A isoforms. Drug Metab Dispos. 34:43–50. 2006. View Article : Google Scholar : PubMed/NCBI
34	Christians U: Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A. Ther Drug Monit. 26:104–106. 2004. View Article : Google Scholar : PubMed/NCBI
35	Matsuda H, Kinoshita K, Sumida A, Takahashi K, Fukuen S, Fukuda T, Takahashi K, Yamamoto I and Azuma J: Taurine modulates induction of cytochrome P450 3A4 mRNA by rifampicin in the HepG2 cell line. Biochim Biophys Acta. 1593:93–98. 2002. View Article : Google Scholar : PubMed/NCBI
36	Tsuda S, Egawa T, Kitani K, Oshima R, Ma X and Hayashi T: Caffeine and contraction synergistically stimulate 5′-AMP-activated protein kinase and insulin-independent glucose transport in rat skeletal muscle. Physiol Rep. 3:e125922015. View Article : Google Scholar : PubMed/NCBI
37	Yang H, Garzel B, Heyward S, Moeller T, Shapiro P and Wang H: Metformin represses drug-induced expression of CYP2B6 by modulating the constitutive androstane receptor signaling. Mol Pharmacol. 85:249–260. 2014. View Article : Google Scholar : PubMed/NCBI
38	Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR and Zhou SF: Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab. 10:730–753. 2009. View Article : Google Scholar : PubMed/NCBI
39	Iber H, Li-Masters T, Chen Q, Yu S and Morgan ET: Regulation of hepatic cytochrome P450 2C11 via cAMP: Implications for down-regulation in diabetes, fasting, and inflammation. J Pharmacol Exp Ther. 297:174–180. 2001.PubMed/NCBI
40	Wang H, Guan W, Yang W, Wang Q, Zhao H, Yang F, Lv X and Li J: Caffeine inhibits the activation of hepatic stellate cells induced by acetaldehyde via adenosine A2A receptor mediated by the cAMP/PKA/SRC/ERK1/2/P38 MAPK signal pathway. PLoS One. 9:e924822014. View Article : Google Scholar : PubMed/NCBI
41	Morgan NG, Blackmore PF and Exton JH: Age-related changes in the control of hepatic cyclic AMP levels by alpha 1- and beta 2-adrenergic receptors in male rats. J Biol Chem. 258:5103–5109. 1983.PubMed/NCBI
42	Yasuda K, Ueno S, Ueda E, Nishikawa M, Takeda K, Kamakura M, Ikushiro S and Sakaki T: Influence of sesamin on CYP2C-mediated diclofenac metabolism: In vitro and in vivo analysis. Pharmacol Res Perspect. 3:e001742015. View Article : Google Scholar : PubMed/NCBI